Company intelligence / Profile preview
Shanghai Longyao Biotechnology Co., Ltd.
Shanghai, Shanghai Municipality, China
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Shanghai Longyao Biotechnology has completed first-in-human dosing in Phase I trials for its CD20-targeted CAR-T product in relapsed/refractory B-cell non-Hodgkin's lymphoma at Ruijin Hospital. The company also has a pipeline of additional autologous and allogeneic immune cell therapies targeting both hematologic and solid tumors. Early results indicate good safety and efficacy profiles for their lead assets.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapy (autologous and allogeneic)TCR-T cell therapyDC vaccine technology (DC1–CTL)NK cell technologyCIK technology
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
GE Healthcare – strategic process development agreement to automate and scale up GMP-compliant production of autologous/allogeneic cellular therapies.AstraZeneca – strategic cooperation on global commercialization/patent licensing of the CD20-OX40 CAR‑T asset.
Beyond the preview
Go deeper on Shanghai Longyao Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Longyao Biotechnology Co., Ltd..